BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Discover Bristol-Myers Squibb's groundbreaking patent for personalized SLE treatment, utilizing IKZF3 gene expression to optimize dosage for better patient outcomes.

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of ... suboptimal response to autologous stem cell transplant. The Cambridge, Mass., company said it expects the move ...

Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly diagnosed multiple myeloma.

A pharmaceutical giant that made a splashy, incentive-backed entrance to Tampa over 10 years ago plans to slash its office ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors.

Squibb founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers invested $5000 into a struggling drug manufacturing firm in Clinton ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) shares are trading lower by 4.11% to $15.62 during Tuesday’s session after the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...